An innovative mental health company remains committed to increasing accessibility to psychedelic-assisted therapies for those in need, and is working on a different way of dispensing relief.
Innovative mental health company Numinus Wellness Inc. (TSX: NUMI) is working to advance safe, evidence-based psychedelic-assisted therapies. In the company’s press release, the firm announced that its research division, Numinus Bioscience, has developed a psilocybin-containing tea bag for use in clinical research. If appropriate regulatory approvals are granted, eventual treatment of clients in psychedelic-assisted therapy.
The research behind the tea bag involved the development of processes and procedures to deliver 25mg per dose and the use of Numinus' validated strains of Psilocybe cubensis. The tea bag will be studied in a phase 1 trial of practitioners receiving experiential training for psilocybin-assisted therapy, with the goal to be used in Numinus' research, including trial partnerships at Cedar Clinical Research, Numinus' clinical trial management division. The product has also been submitted to Health Canada to be included on the psilocybin supplier list for the federal Special Access Program, through which health care providers can apply to provide psilocybin-assisted therapy, among other psychedelic-assisted therapies, to patients with demonstrable need.
AI
Market Data 
Markets 
